Physician profile
Affaf Munir
NPI 1851597470
$2,053.06
in general payments reported to CMS, 2019-2025
27 companies · $827 in 2025
The $827 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $107 · 2021: $115 · 2022: $160 · 2023: $95.43 · 2024: $333 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,255.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $451.96 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $224.64 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $171.56 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $134.62 | 2024-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $126.09 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.12 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $96.61 | 2019-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $87.92 | 2020-2025 | Eliquis |
| Lundbeck LLC | $69.88 | 2024-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $65.56 | 2019-2024 | Verquvo, Gardasil, Gardasil 9 |
| Lilly USA, LLC | $63.72 | 2024-2025 | Mounjaro, Zepbound |
| Csl Behring | $58.24 | 2019 | |
| Daiichi Sankyo INC. | $42.21 | 2024-2025 | Injectafer |
| Axsome Therapeutics, INC. | $36.47 | 2025 | Auvelity |
| Cumberland Pharmaceuticals, INC. | $35.86 | 2024-2025 | Kristalose |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $32.24 | 2024-2025 | |
| Allergan, INC. | $30.39 | 2019 | |
| Exact Sciences Corporation | $29.22 | 2025 | Cologuard Collection Kit |
| Viatris Specialty LLC | $26.53 | 2025 | Yupelri |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.25 | 2020 | |
| Novartis Pharmaceuticals Corporation | $25.25 | 2019 | |
| Edwards Lifesciences Corporation | $24.91 | 2025 | |
| Dexcom, INC. | $24.42 | 2025 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $21.84 | 2024 | |
| Abbott Laboratories | $16.39 | 2025 | Freestyle Libre 3 |
| Abiomed | $14.40 | 2022 | |
| Amgen INC. | $13.76 | 2025 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Affaf Munir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.